Immuneering Corp. (IMRX) said Tuesday it has appointed Thomas Schall as its chair.
Schall has been on Immuneering's board since March 2024 and will support late-stage development and commercialization efforts, the company said.
Immuneering's shares were up over 3% in recent Tuesday premarket activity.